Congratulations to LONGBIO-B (Stock Code: 1779.HK) on the Successful IPO on the Main Board of the HKEX!

Congratulatory

2026/06/05

COMPANY PROFILE

LONGBIO-B is a clinical-stage biopharmaceutical company. Established in 2020 and located in Shanghai and Changshu, Suzhou, China, LONGBIO-B primarily focuses on in-house discovery and development of biopharmaceuticals targeting allergic and autoimmune diseases.

(Source: http://www.longbio.com)

CR SWCS Team is honoured to serve as the Company Secretary of LONGBIO-B, committed to ensuring governance, compliance, and sustained growth.

Other News

CR SWCS Joins ZGC Science City – HK Capital Markets Service Centre as Founding Participant

Events

Congratulations to LONGBIO-B (Stock Code: 1779.HK) on the Successful IPO on the Main Board of the HKEX!

Congratulatory

CR SWCS 2025 Year-in-Review: Professional Services Empower Development, Outstanding Achievements Deliver Impressive Results (Content available in Chinese Only)

NEWS Room

【ESG Outlook】Under the 15th Five-Year Plan, How Can Companies Seize ESG Strategic Opportunities? (Content available in Chinese Only)

Thought Leadership